儿童狼疮达标治疗终点的验证:英国JSLE队列的数据驱动敏感性分析
基于英国JSLE队列研究,采用数据驱动敏感性分析评估儿童起病系统性红斑狼疮(cSLE)达标治疗目标的优化定义。结果显示,将cLLDAS的SLEDAI-2K阈值降至≤3或将PGA阈值降至≤0.25可显著更好预防中重度复发,但未影响新发损伤风险;cCR和cCR-0的变异均无显著改善。
要点
- cLLDAS的SLEDAI-2K≤3或PGA≤0.25变异均显著降低中重度复发风险。
- 上述cLLDAS变异未显著影响新发损伤风险。
- cCR和cCR-0的任何变异均未显著改善复发或损伤风险。
核心结论
- 通过降低SLEDAI-2K至≤3和PGA至≤0.25优化cLLDAS定义,可能增强对中重度复发的保护,但不影响新发损伤。
- cCR和cCR-0定义的变异未显示显著改善中重度复发或新发损伤风险。
研究设计与样本
- 利用英国JSLE队列研究,在每次访视时判定cSLE目标达成情况。
- 采用Prentice-Williams-Peterson(PWP)模型评估目标定义变异对后续中重度复发和新发损伤风险的影响。
- 使用双侧t检验比较原始与变异cSLE目标定义在PWP间隙时间模型中获得的危险比(HR)。
主要发现
- cLLDAS变异:SLEDAI-2K阈值转为≤3,HR 0.13 [0.09, 0.19],P < 0.001;PGA阈值转为≤0.25,HR 0.14 [0.10, 0.20],P < 0.001,均显著更好保护中重度复发。
- 上述cLLDAS变异未影响新发损伤风险。
- cCR和cCR-0的所有变异均未显著改善中重度复发或新发损伤风险(所有P > 0.05)。
- 结合两种变异的改良cLLDAS进一步改善对中重度复发的保护(HR 0.12 [0.08, 0.17],P < 0.001)。
关键数值与推荐
- cLLDAS中SLEDAI-2K≤3变异:HR 0.13 [0.09, 0.19],P < 0.001。
- cLLDAS中PGA≤0.25变异:HR 0.14 [0.10, 0.20],P < 0.001。
- 改良cLLDAS(联合两种变异):HR 0.12 [0.08, 0.17],P < 0.001。
临床怎么用
- 在儿童SLE达标治疗中,可考虑将cLLDAS的SLEDAI-2K阈值降至≤3、PGA阈值降至≤0.25以更好预防中重度复发。
- cCR和cCR-0的现行定义无需基于本研究结果进行修改。
局限性
- 研究基于英国JSLE队列,外部推广性需进一步验证。
- 未报告变异定义对新发损伤风险的显著影响,需长期随访评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To conduct data-driven sensitivity analyses to evaluate whether refined definitions of childhood-onset systemic lupus erythematosus (cSLE) treat-to-target goals provide better protection against moderate-severe flares and new damage, compared with original consensus-derived targets. METHODS: The UK JSLE Cohort Study was utilized. Childhood-SLE target attainment was determined at each visit. Removal or transformation of cSLE target criteria ('variations') were investigated, for Childhood Lupus Low Disease Activity State (cLLDAS), cSLE Clinical Remission on Steroids (cCR) and cSLE Clinical Remission off Steroids (cCR-0). The impact of such variations on the hazards of subsequent moderate-severe flare and new damage was assessed, using Prentice-Williams-Peterson (PWP) models. Two-sided t-tests compared the hazard ratios (HRs) obtained from the PWP gap-time models for the original and varied cSLE target definitions. RESULTS: Two variations of cLLDAS demonstrated significantly better protection against moderate-severe flare, including transformation of SLEDAI-2K cut-off to ≤3 (HR 0.13 [0.09, 0.19], P < 0.001); and transformation of PGA cut-off to ≤0.25 (HR 0.14 [0.10, 0.20], P < 0.001). These variations in cLLDAS did not impact on the hazards of new damage. No variations of cCR and cCR-0 led to a significant improvement in hazards of moderate-severe flare/new damage (all P > 0.05). A modified version of cLLDAS, combining these two transformations was also assessed, demonstrating further improvement in protection against moderate-severe flare (HR 0.12 [0.08, 0.17], P < 0.001). CONCLUSIONS: Refining the cLLDAS definition by lowering the SLEDAI-2K cut-off to ≤3 and PGA to ≤0.25 may enhance protection against moderate-severe flare, but not new damage. No variations of cCR or cCR-0 showed significant improvement.
引用
- Sarker C, Jorgensen AL, Tharmaratnam K, et al. Validating treat-to-target endpoints in childhood lupus: data-driven sensitivity analyses from the UK JSLE cohort study. Rheumatology (Oxford). 2026. PMID: 41557849. doi:10.1093/rheumatology/keag015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。